News

American Association of Individual Investors10h
Which Is a Better Investment, Ionis Pharmaceuticals, Inc. or Neurocrine Biosciences, Inc. Stock?
Learn more about whether Ionis Pharmaceuticals, Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's ...
Here’s Why Clearbridge Growth Strategy Sold AbbVie (ABBV)
ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” first quarter 2025 ...
Ionis Pharmaceuticals price target lowered to $52 from $55 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $52 from $55 and keeps an Equal Weight rating on the shares.
Morgan Stanley Keeps Their Hold Rating on Ionis Pharmaceuticals (IONS)
In a report released today, Michael Ulz from Morgan Stanley maintained a Hold rating on Ionis Pharmaceuticals (IONS – Research Report), with a ...
Healio4d
Hereditary angioedema attacks fall 62% with switch to donidalorsen
Patients with hereditary angioedema who switched from other drugs to donidalorsen for long-term prophylaxis experienced fewer ...
Ionis Pharmaceuticals (IONS) Surges 8.9%: Is This an Indication of Further Gains?
Ionis Pharmaceuticals (IONS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further ...
UVA Today6d
Q&A: Could a New Drug Help Prevent Heart Attacks and Strokes?
UVA professor Dr. Christopher Kramer explains how a new Eli Lilly drug may cut a significant heart attack risk factor by 95%.